Business Information
The group's principal activities are to discover, develop and commercialize novel and improve orally available drugs. It focuses drug discovery efforts across g protein-coupled receptors and compounds within four therapeutic areas: metabolic diseases, central nervous system disorders, cardiovascular diseases and inflammatory disorders. It uses carttm which is its constitutively activated receptor technology, melanophore technology and other proprietary technologies to better understand gpcrs and to identify compounds that may lead to new drugs. The group intends to commercialize drugs independently and through collaborations with pharmaceutical partners.
|
|
Name |
Title
|
Email
|
| Dominic Behan | Co - Founder, Dir., Sr. VP, Chief Scientific Officer | N/A | | Robert Hoffman | VP - Finance, CFO | N/A | | William Shanahan | Chief Medical Officer, VP | N/A | | K. Ajit-Simh | VP - Quality Systems | N/A | | Louis Scotti | VP - Marketing, Business Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 30,569 | (86,248) | | 2005 | 23,233 | (67,901) | | 2004 | 13,686 | (57,992)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
